As of Dec 09
| -0.14 / -2.48%|
The 5 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +45.45% increase from the last price of 5.50.
The current consensus among 8 polled investment analysts is to Hold stock in BioCryst Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.